Actos Link To Bladder Cancer Leads To Decrease In Manufacturer’s Profits

Amid recent warnings from the FDA and the public's mounting worry over evidence that Actos (pioglitazone) may cause bladder cancer, Takeda Pharmaceutical Company is suffering a significant dent in its profits due to falling sales of the once popular diabetic... Read more

0 611

Actos Multidistrict Litigation Pending As EMA And FDA Still Pushing Drug As Second Line Treatment

The European Medicines Agency has recently announced that, despite a serious risk for causing bladder cancer, the prescription medication Actos – or Glustin as it is known in some European countries – should still be prescribed by physicians as a... Read more

0 700

Takeda Attorneys Agree With Plaintiff Claim To Consolidate Actos Lawsuits

Back in August, plaintiffs suing the drug maker Takeda Pharmaceuticals filed motions to consolidate the lawsuits of bladder cancer patients who have taken Takeda’s drug Actos. On September 29, Takeda attorneys filed a response to the U.S. Judicial Panel on... Read more

0 728

Despite Bladder Cancer Risk, European Medicines Agency Does Not Recall Actos

Despite a reported link to an increased risk of bladder cancer, European drug regulators have determined that a recall of the diabetes drug Actos is not necessary. On October 21, 2011 the European Medicines Agency issued a clarification of its... Read more

0 605

Recent Cancer Lawsuits Highlight Alleged Danger of Actos

The U.S. Food and Drug Administration recently announced “that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.” The FDA explains that from January 2010 through October... Read more

Actos

$26,000,000

$25,900,000

$25,000,000